Matinas BioPharma plunges as deal for lead asset falls apart

seekingalpha10-31

cagkansayin/iStock via Getty Images Matinas BioPharma (NYSE:MTNB) lost more than a third of its value on Thursday after the company ended a preliminary agreement related to a potential joint ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479037391?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2075111295/image_2075111295.jpg?io=getty-c-w750","is_english":true,"pubTime":"2024-10-31 23:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479037391","market":"hk","top_or_hot":-1,"title":"Matinas BioPharma plunges as deal for lead asset falls apart","media":"seekingalpha","content":"<div>\n<p>cagkansayin/iStock via Getty Images  Matinas BioPharma (NYSE:MTNB) lost more than a third of its value on Thursday after the company ended a preliminary agreement related to a potential joint ...</p>\n\n<a href=\"https://seekingalpha.com/news/4229413-matinas-bio-pharma-stock-falls-strategic-options\">Source Link</a>\n\n</div>\n","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Matinas BioPharma plunges as deal for lead asset falls apart</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMatinas BioPharma plunges as deal for lead asset falls apart\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-31 23:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4229413-matinas-bio-pharma-stock-falls-strategic-options><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>cagkansayin/iStock via Getty Images  Matinas BioPharma (NYSE:MTNB) lost more than a third of its value on Thursday after the company ended a preliminary agreement related to a potential joint ...</p>\n\n<a href=\"https://seekingalpha.com/news/4229413-matinas-bio-pharma-stock-falls-strategic-options\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MTNB","symbol_name":"Matinas BioPharma Holdings, Inc","start_time":0,"source_url":"https://seekingalpha.com/news/4229413-matinas-bio-pharma-stock-falls-strategic-options","article_id":"2479037391","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2075111295/image_2075111295.jpg?io=getty-c-w750"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479037391","pubTimestamp":1730388304,"columns":[],"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"cagkansayin/iStock via Getty Images  Matinas BioPharma  lost more than a third of its value on Thursday after the company ended a preliminary agreement related to a potential joint development deal for its lead asset, MAT2203. The company said it terminated a non-binding term sheet regarding global rights linked to MAT2203 upon notification from its partner. The Phase 3-ready oral antimicrobial is targeted at invasive fungal infections.  After the setback, Matinas  has decided to cut its workforce by 80%, effective immediately, and end all its R&D activities to save cash. As part of layoffs, the company plans to eliminate 15 positions, including its Chief Medical Officer, Chief Business Officer, and Chief Technology Officer. In addition to a potential sale of MAT2203, Matinas  plans to evaluate various strategic options, including a winddown of its business operations.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MTNB":"Matinas BioPharma Holdings, Inc","BK4139":"生物科技"},"translate_title":"Matinas BioPharma因主要资产交易失败而暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MTNB":0.9},"content_text":"cagkansayin/iStock via Getty Images  Matinas BioPharma (NYSE:MTNB) lost more than a third of its value on Thursday after the company ended a preliminary agreement related to a potential joint development deal for its lead asset, MAT2203. The company said it terminated a non-binding term sheet regarding global rights linked to MAT2203 upon notification from its partner. The Phase 3-ready oral antimicrobial is targeted at invasive fungal infections.  After the setback, Matinas (NYSE:MTNB) has decided to cut its workforce by 80%, effective immediately, and end all its R&D activities to save cash. As part of layoffs, the company plans to eliminate 15 positions, including its Chief Medical Officer, Chief Business Officer, and Chief Technology Officer. In addition to a potential sale of MAT2203, Matinas (MTNB) plans to evaluate various strategic options, including a winddown of its business operations.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479037391"}